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Volume–outcome relationships have been found for management of symptomatic but not for screen-detected, breast cancers. The
study included 2705 patients with breast cancer detected by the Welsh breast cancer-screening programme from its inception in
1989 to 1997. Survival was tracked until 1999. Data validity was assessed for 10% of subjects. Hospitals’ and surgeons’ annual patient
volumes were calculated as indices of specialisation. Effects of hospital and surgeon volumes on survival were estimated using Cox
regression. Surgeons’ and hospitals’ volumes ranged from 1 to 90, and 1 to 86 patients, respectively. Patients managed by higher
volume surgeons survived significantly longer (adjusted hazards ratio for a volume difference of 10 patients per year¼0.90 (95%
confidence intervals 0.84–0.97)). The adjusted hazard ratio for breast cancer survival was similar (0.91 (95% confidence intervals
0.82–1.00)). This association decreased over time. Patients of higher volume surgeons were significantly more likely to have axillary
surgery and impalpable excision biopsies and were less likely to have mastectomy or radiotherapy. Surgeons’ specialisation in
management of screen-detected breast cancers was associated with longer survival, but this effect appeared to decrease over time.
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Providing high-quality care to all patients with cancer was a central
aim of the National Health Service (NHS) National Cancer Plan, a
major part of which was to concentrate cancer care into designated
cancer units and centres (The NHS Cancer Plan, 2000). There is
growing international evidence that women with breast cancer
receive better care when their management is concentrated in
specialised centres with higher levels of expertise, skill and
organisation (Basnett et al, 1992; Iscoe et al, 1994; Lee-Feldstein
et al, 1994; Samet et al, 1994; Scorpiglione et al, 1995). There is,
however, no such evidence for patients with mainly early-stage
cancers detected by screening.
A Scottish study showed a significantly lower relative risk of
death for patients of specialist breast surgeons compared to
patients of nonspecialist breast surgeons (adjusted RR (95%
confidence interval (95% CI)) 0.84 (0.75–0.94)) (Gillis and Hole,
1996). An update of this study showed that the survival advantage
associated with specialist care persisted after the introduction of
screening (Kingsmore et al, 2003). There is also evidence of a
volume–outcome relationship. Two companion studies of breast
cancer in Yorkshire, recently updated, provide relatively strong
evidence of better survival with larger surgeon volumes (Sainsbury
et al, 1995a,b). Another study from the Thames Cancer Registry
found a significant trend with increasing hospital volume of
increasing access to services meeting quality of care criteria for
women with breast cancer (Mikeljevic et al, 2003). Most of these
studies concerned symptomatic breast cancers. None of them
focused solely on breast cancers detected by screening. Patients
with breast cancer detected by screening tend to be at earlier stages
than symptomatic cancers and would tend to have higher cure
rates.
The Welsh breast-screening programme, Breast Test Wales
(BTW), first started screening in February 1989 when the centre in
Cardiff opened serving South East Wales. October 1991 saw the
opening of the centre in Llandudno and the start of screening in
North Wales. This was followed shortly afterwards, in January
1992, with the opening of the Swansea centre serving West Wales.
In the early years of the screening programme, quality assurance
did not extend beyond initial diagnosis and data on subsequent
management were not routinely collected. The production of good
quality surgical data has taken time to develop but has greatly
improved in recent years. This was mainly due to the British
Association of Surgical Oncology (BASO), which in the early 1990s
brought together surgeons working in breast cancer screening. The
BASO Breast Audit Group was set up in order to provide reliable
information on treatment events for women diagnosed through the
UK NHS Breast Screening Programme (NHSBSP) and to assess
surgical performance. It has now become a regular part of the
NHSBSP activity.
The UK programme is thus now subject to stringent quality
assurance, which would be expected to have a beneficial effect on
the care of women with screen-detected breast cancer. Never-
theless, two studies report wide variation between clinicians in the
subsequent management of screen-detected breast cancers
(Chouillet et al, 1994; Moritz et al, 1997). Suboptimal treatment
of breast cancer after diagnosis could potentially compromise the
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seffectiveness of the UK NHSBSP, but the evidence for an
association between specialisation, however defined, and breast
cancer can be confusing. Evidence of a higher volume effect for
screen-detected breast cancer is still lacking. There was thus a need
for a comparative study of the treatment and health outcomes for
screen-detected breast cancer women, taking into account
differences in case mix. Data held by BTW provided an excellent
opportunity to study such issues in Wales. Furthermore, these data
allowed for investigation of the evolution of cancer care over time,
while screening and treatment policies were changing.
The main aims of this study were, therefore, to describe trends
in care processes and outcomes among screen-detected breast
cancer cases in Wales and to examine relationships between
surgeon and hospital volumes and care processes and outcomes.
PATIENTS AND METHODS
The study had a dynamic cohort design. Some data were recorded
before and some were recorded after the start of the study. The
study population comprised all women newly diagnosed by
screening as having breast cancer, and managed by BTW from
the start of screening in February 1989 until a last screening
invitation of 31 March 1997. All patients were diagnosed by
screening, and no symptomatic patients were included.
The primary data were those routinely collected by BTW and
recorded on the BTW database. Sources of these data included the
screening units, the pathology laboratories and surgeons. Surgeons
were responsible for sending completed follow-up data to BTW.
Variables examined in this study were age at diagnosis, year of
diagnosis, postal code, diagnostic investigations (nonsurgical
needle biopsy, impalpable and palpable excision biopsies), the
main treatment (breast conservation therapy (BCT) or mastect-
omy), adjuvant therapy provision (tamoxifen, radiotherapy and
chemotherapy provision), prognostic indicators for invasive
tumours (size, histological grade and spread), recurrences and
deaths (all cause and breast cancer specific).
In all, 15% of women (417 of 2705) had no follow-up visits
recorded on the BTW database suggesting incomplete reporting.
For these women, data were collected from hospital records by PA.
There was also concern by BTW that some adjuvant therapy details
were not being fully reported. In order to validate the data on the
BTW database, 10% of all women were randomly sampled using
computer-generated random numbers, and their hospital records
were examined (by PA). The adjuvant therapy details for this
random sample were also obtained from the women’s hospital
records at the same time as the missing follow-up details. Once the
information had been collected, the data were anonymised.
In cases where there was no record of a woman having received
a treatment, for example, tamoxifen, chemotherapy or radio-
therapy, it was assumed that she did not receive it.
Each woman was allotted a surgeon volume and a hospital
volume, which were the annual patient volumes for their main
surgeon and main hospital. Patient volumes were defined as the
number of newly diagnosed women with screen-detected breast
cancer that was managed by each surgeon or hospital per year.
Each patient’s main surgeon was defined as the surgeon who
carried out the most radical operation, as this was the procedure
most likely to influence survival. Similarly, the hospital where the
most radical surgery was carried out was classed as the main
treatment location. Townsend deprivation scores were derived
from each patient’s postal code, and linked to enumeration district
data from the 1991 census (Morris and Carstairs, 1991).
Patient survival data were tracked with the NHS Central Register
and updated quarterly. The register was last updated for this study
on 31 January 1999. Death details specified dates and primary and
contributory causes of death. Women still alive at this time were
defined as censored in the survival analysis.
Conventional statistical methods were used for summary
descriptions of variables (Hamilton, 1998; Altman, 1991). A 5%
significance level was used. Statistical analysis primarily empha-
sised estimation of differences and ratios, with 95% CI. Propor-
tions were compared using Pearson’s w
2 and exact tests. Trends in
proportions across ordinal categorical variables were tested using
Spearman’s rank correlation or Cuzick’s test for trend (Cuzick,
1985).
Multiple logistic regression was used to examine the indepen-
dent relationships between dichotomous outcome variables and
several explanatory variables. Cox’s proportional hazards model
was used for multivariable survival analysis. Cox regressions were
stratified by variables that had nonproportional hazards (Parmar
and Machin, 1995). Explanatory variables were entered into the
multivariable models if they were thought a priori to be potentially
causally related to or potentially confounding factors for the
outcome of interest. All putative causes preceded their respective
outcomes chronologically. Surgeon and hospital volumes were
included in all models as they were the main explanatory variables
of interest. Adjusted odds ratio and hazards’ ratio (HR) were
estimated by using surgeon and hospital volumes as continuous
variables. They were also transformed into ordinal categorical
variables with low, medium and high volume categories. Cut-
points for choosing high, medium or low volumes were arbitrary
and were the same for both. In secondary survival analyses,
different arbitrary volume cut-points for surgeon volume were also
tested.
For the adjuvant therapy and survival models, analyses were
firstly carried out on all tumours, that is, both invasive and in situ.
The analyses were then repeated for invasive tumours only, so as to
be able to adjust for the prognostic indicators of size, histological
grade and nodal involvement, which are not comparable to in situ
tumours.
The principal unit of analysis was a patient and the
primary analysis assumed independence between women. The
potentially clustered nature of the data necessitated adjustment
for intrasurgeon and intrahospital correlation in the regression
analysis. Adjusted standard errors and 95% CIs were estimated
using Stata’s ‘cluster’ option for regression analyses (STATA,
1999).
RESULTS
Case-mix and surgeon and hospital volumes
A total of 2705 women diagnosed with primary breast cancer were
identified. They were managed by 25 surgeons in 19 hospitals.
Table 1 shows patients’ characteristics for different surgeon
volumes. Most of the women had early-stage cancers. Although
79% were invasive, 76% had no involved nodes, 75% of tumours
were less than 19mm in diameter and 55% had a ‘good’
Nottingham Prognostic Index (Table 2).
Prognostic characteristics of women managed by high, medium
and low-volume surgeons or hospitals did not differ significantly.
Women of lower volume surgeons, however, tended to live in more
affluent areas. Women of lower volume surgeons were also more
likely to have missing tumour grades, missing Nottingham
Prognostic Index and more affected nodes, but these differences
were not significant.
The median annual number of patients seen by each surgeon
and each hospital decreased significantly over time (Po0.01).
Table 3 shows median surgeon and hospital volumes and ranges
for different time periods. The proportion of women managed by
high or medium volume surgeons/hospitals, however, remained
over 95% over time. Only 3% of women were managed by
surgeons, with fewer than 10 cases per year, and only 4% were
managed in hospitals, with fewer than 10 cases per year. Surgeon
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svolume and hospital volume were significantly associated with
each other (Po0.001).
Diagnostic and therapeutic procedures
Most women had a nonsurgical needle biopsy (1784 of 2705), over
a quarter had an impalpable excision biopsy and fewer than 5%
had a palpable excision biopsy. In all, 72 women had no surgical
procedure after diagnosis. Of the 2663 women who did have
therapeutic surgery, nearly half of them had a mastectomy.
Approximately half of all 2705 women received tamoxifen, a third
received radiotherapy and 3% received chemotherapy.
In the multiple logistic models (Table 4), surgeon volume was
independently associated with having a mastectomy, axillary
surgery and being given radiotherapy. With every increase of 10
women per surgeon per year, there was a 6% lower probability of a
woman having a mastectomy rather than BCT, a 22% higher
probability of having axillary surgery and a 10% lower probability
of being given radiotherapy. Surgeon volume was not indepen-
dently associated with having a needle biopsy, tamoxifen or
chemotherapy.
Hospital volume was independently associated with having a
mastectomy, radiotherapy or chemotherapy. With every increase
of 10 women per hospital, there was a 5% higher probability of
having a mastectomy rather than BCT, a 7% higher probability of
having radiotherapy and a 16% lower probability of having
chemotherapy.
Trends over time
Biopsy procedures changed significantly over the study period.
The proportion of women having a diagnostic needle biopsy
increased from 44% in 1989–1990 to 75% in 1996–1997 (Cuzick’s
test for trend, z¼6.10, Po0.01). Consequently, the proportion of
women having an impalpable excision biopsy decreased (Cuzick’s
test for trend, z¼ 3.17, Po0.01). Palpable excision biopsies also
decreased significantly over time (Cuzick’s test for trend,
z¼ 5.08, Po0.01). Mastectomy rates and adjuvant therapy also
changed significantly over time. The proportion of women having
a mastectomy rather than BCT decreased from 56 to 42% (Cuzick’s
test for trend, z¼ 6.64, Po0.01) as did the proportion of women
having axillary surgery (Cuzick’s test for trend, z¼ 4.9, Po0.01).
Radiotherapy and tamoxifen provision increased significantly over
time (Cuzick’s test for trend, z¼7.8, Po0.01, and z¼3.8, P¼0.01,
respectively).
Survival time
During the period of follow-up, 203 of the 2705 (7.4%) women
died, of whom 194 had complete data for survival analysis. A total
of 120 deaths (4.4% of 2705) were attributed to breast cancer and
83 to other causes. Survival was worse for older women, women
with bilateral tumours, invasive tumours, or women having a
mastectomy or receiving chemotherapy (Table 5). For all-cause
survival, higher surgical volumes were independently associated
with longer survival, but higher hospital volumes were not.
Figure 1 shows unadjusted survival results for all-cause survival by
surgeon volume from which clear differences can be seen.
For breast cancer survival, women had a nonsignificantly better
survival if managed by higher-volume surgeons compared with
lower-volume surgeons. Among the 2121 women with invasive
tumours, 181 (8.5%) died, 113 of 2121 (5.3%) were from breast
cancer. In this subgroup, tumour size, histological grade and
number of involved nodes (which were only obtained for invasive
tumours) were shown to be strong independent predictors of both
all-cause and breast cancer survival. Women with large tumours,
tumours with node involvement and tumours of a more severe
histological grade had worse survival (P-values¼0.002, o0.001,
o0.001, respectively, for both all-cause and breast cancer).
Hazard ratios for surgeon and hospital volumes were not
substantially different for the invasive tumour subgroup than for
all patients (HR (95% CI): 0.990 (0.982–0.997, P¼0.009, and 1.003
Table 1 Surgeon volume and patient demographic characteristics, follow-up duration and survival
Surgeon volume
a (N) High (6) (X50) Medium (4) (11–49) Low (15) (p10) Total (25) Test, P-value
Age at diagnosis (years) Spearman’s rank
N (%) 2092 536 76 2704 correlation
Mean (s.d.) 58.6 (5.6) 58.7 (5.7) 58.5 (4.9) 58.5 (5.6) P¼0.48
Range 41.3–81.0 49.2–84.9 41.4–72.9 41.3–84.9
Townsend deprivation score ANOVA
1st quartile (most affluent) 482 (23) 167 (31) 27 (36) 676 (25) P¼0.001
2nd quartile 553 (26) 106 (20) 11 (14) 670 (25)
3rd quartile 511 (24) 142 (26) 21 (28) 674 (25)
4th quartile 539 (26) 118 (22) 17 (22) 674 (25)
Missing
b 7 (0.3) 3 (0.6) 0 10 (0.4)
Follow-up (years) Spearman’s rank
N (%) 2086 534 75 2696 correlation
Median (IQR) 3.0 (1.9–4.2) 3.0 (1.5–4.2) 3.1 (2.0–4.9) 3.0 (1.8–4.2) Po0.001
Missing
b 6 (0.29) 2 (0.37) 1 (1.3) 9 (0.33)
Recurrence Wilcoxin’s rank sum
N (%) 87 (4.2) 26 (4.9) 5 (6.9) 118 (4.4) P¼0.69
All-cause mortality Wilcoxin’s rank sum
N (%) 146 (7.1) 46 (8.6) 11 (4.5) 203 (7.5) P¼0.76
Breast cancer mortality Wilcoxin’s rank sum
N (%) 86 (4.1) 28 (5.2) 6 (7.9) 120 (4.4) P¼0.9996
ANOVA¼analysis of variance; IQR¼interquartile range. All tumours N (%): 2704 (100), one patient with missing surgeon ID.
aSurgeon volume analysed as a continuous
variable.
bMissing values not used in analyses.
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sTable 2 Surgeon volume and treatment and histological prognostic factors
High (6) (X50) Medium (4) (11–49) Low (15) (p10) Total (25) Test, P-value
Surgeon volume
a, N
Therapeutic procedures, N (%) Cusick’s test for trend
BCT 1133 (54) 299 (56) 29 (38) 1461 (54) z¼1.15, P¼0.25
Radiotherapy 724 (35) 169 (32) 615 (20) 908 (34) z¼ 2.6, P¼0.014
Tamoxifen 1129 (54) 211 (39) 21 (28) 1361 (50) z¼ 7.23, Po0.01
Chemotherapy 74 (3.5) 9 (1.7) 4 (5.3) 88 (3.3) z¼ 1.13, P¼0.26
Invasive status, N (%) Wilcoxin’s rank sum
Invasive tumours 1636 (78) 422 (79) 63 (83) 2121 (78) P¼0.97
In situ tumours 448 (21) 112 (21) 12 (16) 572 (21)
Missing
b 8 (0.38) 2 (0.37) 1 (1.32) 11 (0.41)
All tumours 2092 536 76 2704
Invasive tumours only
c, N (%): 2121 (100)
Malignant nodes
a Spearman’s rank
None 1221 (75) 312 (74) 37 (59) 1570 (74) correlation
Few (1–4) 299 (18) 79 (19) 18 (29) 396 (19) P¼0.59
Medium (5–9) 60 (3.7) 14 (3.3) 3 (4.8) 77 (3.6)
Lots (X10) 18 (1.1) 9 (2.1) 0 27 (1.3)
Missing
b 38 (2.3) 8 (1.9) 5 (7.9) 51 (2.4)
Size (mm)
a, N 1620 417 60 2097 Spearman’s rank
Median (IQR) 13 (9–18) 13 (9–19) 15 (10.5–22) 13 (9–18) correlation
Range 1–99 1–99 2–60 1–99 P¼0.53
Missing
b 16 (0.8) 5 (0.9) 3 (3.9) 24 (0.9)
Grade
1 528 (32) 115 (27) 10 (16) 653 (31) Cusick’s test
2 711 (43) 181 (43) 27 (43) 919 (43) for trend
3 224 (14) 55 (13) 9 (14) 288 (14) P¼0.85
Missing
b 173 (11) 71 (17) 17 (27) 261 (12)
NPI
a Spearman rank
Good 936 (57) 220 (52) 19 (30) 1175 (55) Correlation
Moderate 391 (24) 106 (25) 19 (30) 516 (24) P¼0.94
Poor 87 (5.3) 17 (4.0) 4 (6.4) 108 (5.1)
Missing
b 222 (14) 79 (19) 21 (33) 322 (15)
BCT¼breast conservation therapy; IQR¼interquartile range. All tumours, N (%): 2704 (100), one patient with missing surgeon ID.
aSurgeon volume, malignant nodes, size and
Nottingham Prognostic Index analysed as continuous variables.
bMissing values not included in analyses.
cThese data not available for noninvasive tumours.
Table 3 Surgeon and hospital patient volumes for different time-periods
Period 1988–1993 1993–1995 1995–1997 Total Cusick’s test for trend
a
Surgeon volume
b 67 (47–90) 1–90 58 (51–67) 1–90 58 (51–67) 1–90 65 (51–90) 1–90 z¼ 14.72, Po0.01
Hospital volume
b 83 (64–86) 1–86 68 (44–83) 1–86 64 (34–83) 1–86 68 (44–83) 1–86 z¼ 18.66, Po0.01
aSurgeon and hospital volumes, and year analysed as continuous variables.
bMedian (interquartile range) range.
Table 4 Effect of a difference in surgeon
a or hospital volume
a of 10 women on the provision of diagnostic and therapeutic procedures: logistic regression
models
a
Outcome variable % received Explanatory variable Adjusted odds ratio 95% CI P-value
Needle biopsy
b 66.0 Surgeon volume 1.00 0.96–1.05 0.84
Mastectomy
c 47.2 Surgeon volume 0.94 0.90–0.98 0.007
Hospital volume 1.05 1.01–1.08 0.011
Axillary surgery
d 93.5 Surgeon volume 1.22 1.10–1.34 o0.001
Radiotherapy
e 40.3 Surgeon volume 0.91 0.85–0.98 0.015
Hospital volume 1.07 1.01–1.14 0.024
Tamoxifen
f 56.3 Surgeon volume 1.04 0.98–1.10 0.20
Chemotherapy
g 3.8 Hospital volume 0.85 0.76–0.95 0.006
CI¼confidence interval.
aSurgeon and hospital volume analysed as continuous variables and included in all models.
bAlso adjusted for age, centre and period.
cAlso adjusted for
age, centre, period, bilateral tumours, invasive status and the Townsend Deprivation Score.
dAlso adjusted for centre, period, therapeutic procedure and bilateral tumours.
eAlso
adjusted for centre, period, therapeutic procedure, tamoxifen, size, grade and nodal status.
fAlso adjusted for centre, period, therapeutic procedure, age, size, grade and nodal
status.
gAlso adjusted for age, size, grade and nodal status.
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HR for surgeon volume for breast cancer survival for women with
invasive tumours was similar to that from all cause (HR (95% CI):
0.991 (0.981–1.001, P¼0.08)), although the difference was
marginally nonsignificant owing to fewer events. Residence in a
more or less deprived area did not influence survival in any of the
analyses (P¼0.83).
When time trends were examined, the association between
surgeon volume and survival decreased over time. The HR
associated with a difference in surgeon volume of 10 women was
0.86 (95% CI: 0.78–0.94) in women diagnosed during 1988–1993,
0.97 (95% CI: 0.93–1.13) in women diagnosed during 1993–1995
and 0.99 (95% CI: 0.97–1.23) in women diagnosed during 1995–
1997. However, this trend was not statistically significant (P-value
for adding period volume interaction term to the model¼0.57).
These findings were robust despite extensive sensitivity analyses
using alternative methods of data analysis, including examining
survival until death from breast cancer, different periods of follow-
up, different ways of calculating surgeon and hospital volumes,
different ways of dealing with missing prognostic and adjuvant
therapy data, and adjustment for clustering of outcomes within
surgeons and hospitals.
Completeness of BTW data
In all, 15% (417 of 2705) of women had missing follow-up data
recorded at BTW. Results of the regression analysis showed that,
overall, surgeon volume was the strongest predictor of whether
data for follow-up visits were recorded or not (Po0.001). As
surgeon volume increased, information for follow-up visits was
more likely to be recorded. Hospital volume and period of
diagnosis also significantly influenced the recording of follow-up
information (Po0.001 for both). Data were less likely to be
missing as hospital volume increased, or if a woman was diagnosed
in the screening period 1993–1995 compared to the earliest
diagnostic period, 1988–1993.
Validation of the 10% random sample estimated the sensitivity
of BTW data, defined as the proportion of patients for whom an
item recorded in hospital files was also recorded by BTW. This
showed that, for radiotherapy provision, sensitivity ranged from
58% for low-volume surgeons to 80% for high-volume surgeons.
For tamoxifen provision, sensitivity was 62% for high-volume
surgeons compared with 43% for low-volume surgeons. Sensitiv-
ities for both radiotherapy and tamoxifen provision differed
significantly between higher- and lower-volume surgeons (P¼0.06
and 0.001, respectively).
In the survival models, sensitivity analyses were conducted to
assess the robustness of results to assumptions about the validity
of information on radiotherapy and tamoxifen provision. This
Table 5 Significant
a predictors of survival time until death from any cause: Cox’s proportional-hazards model
Crude HR 95% CI Adjusted HR
b 95% CI Adjusted P-value
Explanatory variable
Surgeon volume
d 0.91 0.85-0.097 0.90 0.84–0.97 0.008
Hospital volume
d 1.00 0.94–1.06 1.04 0.98–1.12 0.213
Age at diagnosis (per year) 1.04 1.01–1.06 1.04 1.02–1.07 0.001
Invasive vs in situ 2.49 1.55–3.99 2.33 1.39–3.90 0.0003
Bilateral vs unilateral 3.35 1.82–6.15 2.93 1.54–5.87 0.005
Mastectomy vs BCT 2.09 1.55–2.82 1.79 1.32–2.44 0.0001
Invasive tumours, N¼2121 (100%)
Surgeon volume
d 0.91 0.85–0.97 0.91 0.84–0.98 0.011
Hospital volume
d 1.00 0.94–1.06 1.03 0.84–0.97 0.009
Age at diagnosis (per year) 1.04 1.10–1.06 1.03 0.96–1.11 0.38
Bilateral vs unilateral 3.35 1.82–6.15 2.31 1.00–1.06 0.05
Mastectomy vs BCT 2.09 1.55–2.82 1.46 1.15–4.63 0.02
Chemotherapy vs none 6.40 4.26–9.63 2.35 1.04–2.05 0.03
Size 1.03 1.02–1.04 1.02 1.40–3.94 0.001
Grade 1 vs
grade 2 1.52 1.00–2.33 1.23 1.01–1.03 0.002
grade 3 5.09 3.33–7.78 3.00 0.80–1.90 o0.0001
Missing grade 3 1.34 0.76–2.37 0.94 1.91–4.72 o0.0001
No malignant nodes vs
1–4 2.31 1.63–3.28 1.65 0.52–1.71
5–9 7.08 4.50–11.13 3.47 1.14–2.38
X10 12.48 7.08–21.99 4.26 2.06–5.86
2.19–8.29
CI¼confidence interval; HR¼hazards ratio. All tumours, N¼2705 (100%).
aHospital volume not significant, but included because it is one of the main explanatory variables of
interest.
bAdjusted for all the other variables in the model except for size, grade and malignant nodes, which were only relevant to the invasive tumours model.
dFor a difference
in mean volume of 10 patients per year.
Kaplan−Meier survival estimates, by surgvol
Analysis time (years)
0 5 10
0.6
0.75
1
High
Med
Low
Figure 1 Kaplan–Meier survival curve by surgeon volume.
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sentailed assuming, first, that those with no information had
received these treatments and, second, that they had not. Changing
these assumptions did not substantially change the results.
DISCUSSION
This study shows that specialisation, as indicated by the annual
caseload of surgeons and to a lesser extent hospitals, influenced the
choice of surgical treatment, adjuvant therapy provision and
survival time during the first decade of the breast-screening
programme. It therefore supports the specialisation of early breast
cancer care. Higher-volume surgeons were more likely to provide
more effective treatment (axillary surgery), were less likely to
provide the most traumatic treatments (mastectomy) and obtained
the longest survival, independently of prognostic features. While
the greatest problems with management and outcomes appeared to
be at the lowest end of the surgeon volume spectrum, there were
no clear volume thresholds.
For many of the variables measured, including treatment
procedures and survival, there were consistent and significant
trends of better clinical practice associated with increasing surgeon
volume. This was not so evident with increasing hospital volume,
suggesting that a woman’s breast cancer management was
influenced more by the experience of the surgeon in whose care
she was than by the experience of the hospital in which she was
treated. This may explain the surprising association between
hospital volume and main treatment procedure despite the positive
correlation between surgeon and hospital volumes; one would
expect that the choice of treatment would depend primarily on the
surgeon rather than on the hospital. However, over 25% of lower
volume surgeons also worked in higher volume hospitals,
suggesting that these hospitals needed to address the problem of
unspecialised surgeons within them.
Volume–outcome relationships for breast cancer survival were
very similar to those for all-cause survival, although they were not
statistically significant. Our figures were very similar to those in
the Yorkshire study where an HR (95% CI) associated with a
surgeon who managed 30 or more new cases of invasive breast
cancer per year compared to one who managed 10 or less was 0.85
(0.77–0.93) (Sainsbury et al, 1995a). In our study, a difference of
20 women per surgeon per year in the model for all tumours
gave an HR (95% CI) of 0.85 (0.74–0.98) for all-cause mortality
and 0.85 (0.71–1.02) for breast cancer mortality. For invasive
tumours only, for a difference of 20 women per year, we found HRs
of 0.82 (0.71–0.96) for all-cause mortality and 0.82 (0.67–1.02) for
breast cancer mortality. Although the Yorkshire study involved
many more patients than our study and could therefore generalise
with more confidence than ours, it does suggest that the main
findings of the Yorkshire study may be generalised to women with
earlier, screen-detected, cancers. Unlike the Yorkshire study, this
study found no clear threshold for effects of surgeon volumes on
survival.
Clinical management improved over time, varied between the
three centres and appeared to be most in keeping with practice
guidelines among women of higher volume surgeons. Lower-
volume surgeons tended to perform more invasive surgery and
were less likely to follow guidelines regarding axillary surgery and
adjuvant therapy provision. Provision of tamoxifen and che-
motherapy were, however, not associated with surgeon volume
(HR: 1.003 (0.998–1.008), P¼0.236, and 1.007 (0.993–1.21),
P¼0.327, respectively). Results suggested that older and less
affluent women were not discriminated against with regard to
specialist care. In this study, social deprivation did not appear to
be an important prognostic factor in any of the Cox analyses. This
has also been found by Haybittle et al (1997).
This study is original in that it measures the relationship
between specialisation, as estimated by surgeon and hospital
caseload, and outcomes in the breast-screening population of an
entire NHS region. Other key strengths of this study include the
large sample size, the prospective cohort design and the inclusion
of a wide range of clinical data, which allowed for a thorough
analysis controlling for these variables. All cases were tracked for
survival. The use of surgeon and hospital volumes proved a robust
and objective measure of specialisation.
In calculating surgeon and hospital volumes, this study
could not take into account surgeons’ experience in management
of symptomatic nonscreening-detected breast cancer, which
could plausibly affect their skills in managing screen-detected
cancers. Total breast cancer volumes, which may thus be a
more relevant index of specialisation, would be greater than the
volumes for screen-detected breast cancers used in this study,
but would be unlikely to affect our main findings if volumes
of symptomatic and screen-detected patients were highly
correlated. Surgeon’s total breast cancer volumes could be
estimated by analysis of cancer registry data and hospital
episode statistics, but these data are not held by BTW and so
were beyond the scope of this study. This deserves further
investigation, however, and we are currently investigating
the value of linked cancer registry data and hospital episode
statistics to assess volume–outcome relationships in another
region.
If, as is common practice, patients with impalpable breast
cancers were selectively referred to a few designated surgeons,
while all other patients were referred to local breast surgeons, then
it is possible that patients of lower-volume surgeons, as defined by
us, could tend to have less advanced disease, with better outcomes.
However, this does not appear to be the case in this study. Patients
of lower-volume surgeons did not have smaller or less invasive
tumours (Table 2). Impalpable tumours were not recorded as such.
And patients of lower volume surgeons tended to have poorer, not
better, outcomes. So this kind of selective referral, if present,
would tend to dilute the volume–outcome associations we have
shown here, rather than spuriously to produce associations when
none existed.
This study’s observational design shows what actually happens
in practice when screening and treatment are applied to large
populations. However, observational studies are susceptible to
confounding. Differences in disease severity between women of
higher- and lower-volume surgeons and hospitals are of particular
concern. For this reason, efforts were made to obtain valid data on
baseline prognostic factors and treatments. These data were
generally more complete than most cancer registries would allow.
The study carefully measured and controlled for the main
prognostic factors. Secondary analyses were carried out which
supported the main results, suggesting that confounding was not a
major problem in this study.
Although breast cancer care is multidisciplinary, embracing
many health professions and specialities, there still appeared to be
a small proportion of surgeons not actively participating in best
protocol. Although approximately 97% of women in this study
were treated by relatively high-volume surgeons, 3% were
managed by surgeons treating on average less than nine women
per year and these women had worse survival. Surgeons (40% ) in
the low-volume category managed an average of only one
screening case per year. This is a cause for concern and needs to
be investigated further. Surgeon volume is now addressed each
year in the BASO audit. Breast cancer should be cared for by
surgeons with a specialist interest in breast cancer and a high
breast cancer caseload.
Follow-up audit is essential for continuing quality improvement.
It would also be valuable to continue to monitor survival over
longer periods, given the relatively low mortality rates in the
earlier years after screening. This study shows the value of
collection and analysis of case mix and outcome data in addition to
examination of care processes alone.
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